Actelion Pharmaceuticals Ltd.
http://www1.actelion.com/en/index.page
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Actelion Pharmaceuticals Ltd.
For BMS, Launching New Products Is The Start Of The Battle
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve access to lifesaving therapies. Payers and politicians must be persuaded to loosen their purse strings – and open their minds.
Obesity Gold Rush To Drive Significant Spending Growth Through Decade, IQVIA Says
IQVIA’s latest usage and spending trends report forecasts US obesity market will grow to $35bn by 2028, while the two leading GLP-1 agonists have already posted eye-popping sales growth.
With Vertex Pain Drug Filed At FDA, Commercial Ramp Is Under Way
The company initiated a rolling NDA submission for suzetrigine for acute pain, positioning the drug for a launch in 2025.
Zenas Raises $200m For Bifunctional Antibody In Autoimmune Diseases
Zenas BioPharma plans to have data from four trials – two under way and two starting this summer – for obexelimab, which targets CD19 and FcγRIIb, within about a year and a half.
Company Information
- Other Names / Subsidiaries
-
- Ceptaris Therapeutics, Inc. (Yaupon Therapeutics, Inc.)
- CoTherix, Inc
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice